Rapid single-tier serodiagnosis of Lyme disease.

Autor: Ghosh R; Bioengineering Department, University of California, Los Angeles, CA, 90095, USA., Joung HA; Electrical & Computer Engineering Department, University of California, Los Angeles, CA, 90095, USA.; California NanoSystems Institute (CNSI), University of California, Los Angeles, CA, 90095, USA., Goncharov A; Electrical & Computer Engineering Department, University of California, Los Angeles, CA, 90095, USA.; California NanoSystems Institute (CNSI), University of California, Los Angeles, CA, 90095, USA., Palanisamy B; Bioengineering Department, University of California, Los Angeles, CA, 90095, USA., Ngo K; Bioengineering Department, University of California, Los Angeles, CA, 90095, USA., Pejcinovic K; Bioengineering Department, University of California, Los Angeles, CA, 90095, USA., Krockenberger N; Bioengineering Department, University of California, Los Angeles, CA, 90095, USA., Horn EJ; Lyme Disease Biobank, Portland, Oregon, OR, 97221, USA., Garner OB; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, 90095, USA., Ghazal E; Department of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, NY, 10595, USA., O'Kula A; Department of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, NY, 10595, USA., Arnaboldi PM; Department of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, NY, 10595, USA.; Biopeptides, Corp, Ridgefield, CT, 06877, USA., Dattwyler RJ; Department of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, NY, 10595, USA.; Biopeptides, Corp, Ridgefield, CT, 06877, USA., Ozcan A; Bioengineering Department, University of California, Los Angeles, CA, 90095, USA. ozcan@ucla.edu.; Electrical & Computer Engineering Department, University of California, Los Angeles, CA, 90095, USA. ozcan@ucla.edu.; California NanoSystems Institute (CNSI), University of California, Los Angeles, CA, 90095, USA. ozcan@ucla.edu.; Department of Surgery, University of California, Los Angeles, CA, 90095, USA. ozcan@ucla.edu., Di Carlo D; Bioengineering Department, University of California, Los Angeles, CA, 90095, USA. dicarlo@ucla.edu.; California NanoSystems Institute (CNSI), University of California, Los Angeles, CA, 90095, USA. dicarlo@ucla.edu.; Department of Mechanical Engineering, University of California, Los Angeles, CA, 90095, USA. dicarlo@ucla.edu.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2024 Aug 20; Vol. 15 (1), pp. 7124. Date of Electronic Publication: 2024 Aug 20.
DOI: 10.1038/s41467-024-51067-5
Abstrakt: Point-of-care serological and direct antigen testing offers actionable insights for diagnosing challenging illnesses, empowering distributed health systems. Here, we report a POC-compatible serologic test for Lyme disease (LD), leveraging synthetic peptides specific to LD antibodies and a paper-based platform for rapid, and cost-effective diagnosis. Antigenic epitopes conserved across Borrelia burgdorferi genospecies, targeted by IgG and IgM antibodies, are selected to develop a multiplexed panel for detection of LD antibodies from patient sera. Multiple peptide epitopes, when combined synergistically with a machine learning-based diagnostic model achieve high sensitivity without sacrificing specificity. Blinded validation with 15 LD-positive and 15 negative samples shows 95.5% sensitivity and 100% specificity. Blind testing with the CDC's LD repository samples confirms the test accuracy, matching lab-based two-tier results, correctly differentiating between LD and look-alike diseases. This LD diagnostic test could potentially replace the cumbersome two-tier testing, improving diagnosis and enabling earlier treatment while facilitating immune monitoring and surveillance.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: